characterized newly diagnosed MM patients with bi-allelic TP53 aberrations as a distinct high-risk subgroup with rapid disease progression and extremely aggressive behavior despite the use of combination treatments of PIs, IMiDs, glucocorticoids and cyclophosphamide (190). This evidence concerns the gene TP53 and Miyoshi myopathy.